Vifor Plots Veltassa Growth In Face Of Emerging AstraZeneca Threat
Executive Summary
Vifor sees European market access and clinical cardiology data as key growth drivers for the hyperkalaemia treatment, which now faces competition from AstraZeneca’s much-delayed Lokelma.